Analyst Price Targets — SKYE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 6, 2025 4:12 pm | — | Craig-Hallum | $2.00 | $1.88 | TheFly | Skye Bioscience downgraded to Hold from Buy at Craig-Hallum |
| October 6, 2025 2:19 pm | — | Cantor Fitzgerald | $2.00 | $2.12 | TheFly | Skye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald |
| September 10, 2024 4:30 am | Jonathan Wolleben | JMP Securities | $15.00 | $6.35 | TheFly | Skye Bioscience initiated with an Outperform at JMP Securities |
| August 26, 2024 8:15 am | Albert Lowe | Craig-Hallum | $18.00 | $5.97 | StreetInsider | Craig-Hallum Reiterates Buy Rating on Skye Bioscience (SKYE) |
| June 10, 2024 5:17 pm | Jay Olson | Oppenheimer | $21.00 | $9.98 | StreetInsider | Skye Bioscience (SKYE) PT Lowered to $21 at Oppenheimer |
| May 23, 2024 6:05 am | Kristen Kluska | Cantor Fitzgerald | $21.00 | $11.98 | TheFly | Skye Bioscience initiated with an Overweight at Cantor Fitzgerald |
| April 11, 2024 4:14 pm | Jay Olson | Oppenheimer | $25.00 | $12.69 | StreetInsider | Oppenheimer Starts Skye Bioscience (SYKE) at Outperform Following Uplisting to Nasdaq (correction) |
| March 14, 2024 10:41 am | Edward Tenthoff | Piper Sandler | $20.00 | $12.90 | StreetInsider | Skye Bioscience (SKYE) PT Raised to $20 at Piper Sandler |
Latest News for SKYE
Skye Bioscience (NASDAQ: SKYE) and privately held Redx announced a definitive transaction agreement that would combine the companies into a Nasdaq-listed fibrosis-focused biotechnology company named Fibrx Therapeutics. The transaction, unanimously approved by both companies' boards, is expected to close in the fourth quarter of 2026, subject to shareholder approvals, customary closing conditions, approval of the Redx
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company's lead program will be RXC008, Redx's GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, with an open U.S. IND, FDA Fast Track designation, and a planned Phase 2 clinical study Concurrent aggregate financings of approximately $125…
Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report)'s share price was up 2.8% during mid-day trading on Monday. The stock traded as high as $0.5918 and last traded at $0.5842. Approximately 102,145 shares were traded during trading, a decline of 16% from the average session volume of 122,073 shares. The stock had previously closed
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SKYE.
U.S. House Trading
No House trades found for SKYE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.